Condition: Peripheral Vascular Diseases · Kidney Diseases · Sponsor: University of Leipzig
The primary objective of the trial is to evaluate if an iodinated contrast medium sparing strategy using automated Carbon Dioxide (CO2) Injection prevents Major Adverse Kidney Events up to 90 days (MAKE90) in patients at moderately elevated risk for contrast-associated acute kidney injury (CA-AKI) undergoing infrainguinal peripheral vascular interventions (PVI).
This description comes directly from the study's public registry record.
Sabine Steiner, Prof Dr · +493419718770 · angiologie@medizin.uni-leipzig.de
Always discuss trial participation with your own doctor first.
| Tirol Kliniken Innsbruck | Innsbruck, Austria | Recruiting |
| Universitätsklinik für Innere Medizin II | Vienna, Austria | Recruiting |
| Kreiskrankenhaus Alsfeld | Alsfeld, Germany | Recruiting |
| Universitäts-Herzzentrum Freiburg-Bad Krozingen | Bad Krozingen, Germany | Recruiting |
| Universitätsklinikum Bonn | Bonn, Germany | Not Yet Recruiting |
| Klinikum Chemnitz gGmbH | Chemnitz, Germany | Not Yet Recruiting |
| DIAKO Krankenhaus gGmbH Flensburg | Flensburg, Germany | Not Yet Recruiting |
| MVZ CCB Frankfurt und Main-Taunus GbR | Frankfurt a.M., Germany | Recruiting |
| Universitätsklinikum Leipzig | Leipzig, Germany | Recruiting |
| Klinikum rechts der Isar der Technischen Universität München | München, Germany | Recruiting |
| GRN - Klinik Weinheim | Weinheim, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06656988